• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3'-叠氮-3'-脱氧胸苷的细胞毒性与3'-叠氮胸苷-5'-单磷酸(AZTMP)水平相关,而在培养的CEM T淋巴母细胞中,抗人类免疫缺陷病毒(HIV)活性与3'-叠氮胸苷-5'-三磷酸(AZTTP)水平相关。

Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.

作者信息

Törnevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S

机构信息

Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.

出版信息

Biochem Pharmacol. 1995 Mar 15;49(6):829-37. doi: 10.1016/0006-2952(94)00453-s.

DOI:10.1016/0006-2952(94)00453-s
PMID:7702641
Abstract

Activation of the anti-human immunodeficiency virus (HIV) compound 3'-azido-3'-deoxythymidine (AZT) is dependent on its 5'-phosphorylation by cellular nucleoside and nucleotide kinases. Azidothymidine 5'-triphosphate (AZTTP) is considered to be the metabolite responsible for both the anti-HIV effect of AZT, via inhibition of reverse transcriptase, and cytoxicity by interference with cellular DNA polymerases. During the characterization of AZT metabolism in cultured human T-lymphoblastoid CEM cells, a spontaneously occurring variant cell line, CEM/Ag-1, was found that showed approximately 10-fold resistance to AZT growth inhibition as compared to wild type (wt) cells (EC50 = 2 mM as compared to 350 microM for wt cells). CEM/Ag-1 cells had a 3-fold reduced capacity to accumulate azidothymidine monophosphate (AZTMP) compared to wt cells whereas similar levels of AZTTP were found in both cell lines. The intracellular half-life of AZTMP was approximately 70 min in both wt and CEM/Ag-1 cells. A 3-fold lower specific activity of cytoplasmic thymidine kinase was observed in CEM/Ag-1 extracts as compared to wt. The reduced thymidine kinase activity was not correlated to a decreased level of thymidine kinase mRNA. Syncytium formation of CEM/Ag-1 cells infected with HIV-2 as well as HIV-1 antigen production was inhibited at the same concentrations of AZT (approx. 0.01 microM) as were HIV-1 and HIV-2 infected wt cells. Thus, minor decreases in cellular thymidine kinase levels may markedly affect the cytoxicity of AZT but have no major effect on the antiviral activity of AZT. Our results strongly suggest that AZTMP is responsible for a major part of the growth inhibitor effects, while AZTTP mainly mediates the antiviral activity of AZT.

摘要

抗人类免疫缺陷病毒(HIV)化合物3'-叠氮基-3'-脱氧胸苷(AZT)的激活依赖于细胞核苷和核苷酸激酶对其进行的5'-磷酸化。叠氮胸苷5'-三磷酸(AZTTP)被认为是通过抑制逆转录酶产生AZT抗HIV效应以及通过干扰细胞DNA聚合酶产生细胞毒性的代谢产物。在对培养的人T淋巴母细胞样CEM细胞中AZT代谢的表征过程中,发现了一种自发产生的变异细胞系CEM/Ag-1,与野生型(wt)细胞相比,它对AZT生长抑制的抗性约为10倍(wt细胞的EC50为350 microM,而CEM/Ag-1细胞的EC50为2 mM)。与wt细胞相比,CEM/Ag-1细胞积累叠氮胸苷单磷酸(AZTMP)的能力降低了3倍,而在两种细胞系中发现的AZTTP水平相似。在wt细胞和CEM/Ag-1细胞中,AZTMP的细胞内半衰期约为70分钟。与wt相比,在CEM/Ag-1提取物中观察到细胞质胸苷激酶的比活性低3倍。胸苷激酶活性的降低与胸苷激酶mRNA水平的降低无关。感染HIV-2的CEM/Ag-1细胞的合胞体形成以及HIV-1抗原的产生在与感染HIV-1和HIV-2的wt细胞相同浓度的AZT(约0.01 microM)下受到抑制。因此,细胞胸苷激酶水平的轻微降低可能会显著影响AZT的细胞毒性,但对AZT的抗病毒活性没有重大影响。我们的结果强烈表明,AZTMP是生长抑制作用的主要原因,而AZTTP主要介导AZT的抗病毒活性。

相似文献

1
Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.3'-叠氮-3'-脱氧胸苷的细胞毒性与3'-叠氮胸苷-5'-单磷酸(AZTMP)水平相关,而在培养的CEM T淋巴母细胞中,抗人类免疫缺陷病毒(HIV)活性与3'-叠氮胸苷-5'-三磷酸(AZTTP)水平相关。
Biochem Pharmacol. 1995 Mar 15;49(6):829-37. doi: 10.1016/0006-2952(94)00453-s.
2
Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine).环柳基 3'-叠氮基-2',3'-双脱氧胸苷单磷酸(3'-叠氮基-2',3'-双脱氧胸苷(齐多夫定)的前药)的细胞内代谢
Mol Pharmacol. 1999 Dec;56(6):1354-61. doi: 10.1124/mol.56.6.1354.
3
Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).去羟肌苷(ddI)单独及与齐多夫定(AZT)联合用于人T细胞的药效学研究(PD);一种关于抗逆转录病毒核苷类药物联合抑制HIV逆转录酶(RT)的随机生化方法。
In Vivo. 2000 May-Jun;14(3):377-88.
4
Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM).
Mol Pharmacol. 1990 May;37(5):665-70.
5
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1.M184V突变降低了1型人类免疫缺陷病毒逆转录酶对齐多夫定5'-单磷酸(AZTMP)的选择性切除。
J Virol. 2002 Apr;76(7):3248-56. doi: 10.1128/jvi.76.7.3248-3256.2002.
6
Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection.T淋巴细胞白血病细胞系(Jurkat E6-1/AZT-100)以及HIV-1感染的儿科患者中对叠氮胸苷产生耐药性的体外发育证据。
J Acquir Immune Defic Syndr (1988). 1993 Dec;6(12):1287-96.
7
2',3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine.2',3'-二脱氧胞苷对培养的人CEM T淋巴母细胞的毒性:与3'-叠氮-3'-脱氧胸苷和胸苷联合使用的效果
Mol Pharmacol. 1990 Aug;38(2):237-43.
8
Intracellular metabolism of 3'-azidothymidine in isolated human peripheral blood mononuclear cells.3'-叠氮胸苷在分离的人外周血单个核细胞中的细胞内代谢
AIDS Res Hum Retroviruses. 1991 Sep;7(9):751-9. doi: 10.1089/aid.1991.7.751.
9
Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.叠氮胸苷耐药的人类免疫缺陷病毒1逆转录酶与3'-叠氮-3'-脱氧胸苷5'-单磷酸终止引物的结合增强。
J Biol Chem. 1998 Jun 5;273(23):14596-604. doi: 10.1074/jbc.273.23.14596.
10
3'-Azido-3'-deoxythymidine-(5')-tetraphospho-(5')-adenosine, the product of ATP-mediated excision of chain-terminating AZTMP, is a potent chain-terminating substrate for HIV-1 reverse transcriptase.3'-叠氮-3'-脱氧胸苷-(5')-四磷酸-(5')-腺苷,即ATP介导切除链终止性齐多夫定单磷酸酯的产物,是HIV-1逆转录酶的一种强效链终止底物。
Biochemistry. 2007 Jan 23;46(3):828-36. doi: 10.1021/bi061364s.

引用本文的文献

1
Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.解析复发急性髓系白血病患者化疗耐药的分子机制:迈向克服耐药性的精准医学。
Cancer Cell Int. 2021 Jan 14;21(1):53. doi: 10.1186/s12935-021-01746-w.
2
Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals.三磷酸核苷的亲脂性前药作为生化探针和潜在的抗病毒药物。
Nat Commun. 2015 Oct 27;6:8716. doi: 10.1038/ncomms9716.
3
SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.
SAMHD1对HIV核苷类逆转录酶抑制剂的疗效有不同影响。
Antimicrob Agents Chemother. 2014 Aug;58(8):4915-9. doi: 10.1128/AAC.02745-14. Epub 2014 May 27.
4
Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.血清胸苷激酶 1 浓度作为化疗治疗非霍奇金淋巴瘤患者的预后因素。
J Cancer Res Clin Oncol. 2010 Aug;136(8):1193-9. doi: 10.1007/s00432-010-0769-z. Epub 2010 Feb 7.
5
Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.在 HIV-1 感染者中,amdoxovir 与齐多夫定低剂量和标准剂量之间不存在药代动力学相互作用。
Antimicrob Agents Chemother. 2010 Mar;54(3):1248-55. doi: 10.1128/AAC.01209-09. Epub 2009 Dec 28.
6
The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells.与其他正常和恶性肾细胞相比,增殖标志物胸苷激酶 1 水平在正常肾小管细胞中较高。
Pathol Oncol Res. 2010 Jun;16(2):277-83. doi: 10.1007/s12253-009-9222-5. Epub 2009 Dec 3.
7
Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.使用群体药代动力学和酶动力学模拟模型,开发齐多夫定与选择K65R突变的药物联合制剂的优化剂量。
Antimicrob Agents Chemother. 2008 Dec;52(12):4241-50. doi: 10.1128/AAC.00054-08. Epub 2008 Oct 6.
8
A computational model of mitochondrial AZT metabolism.线粒体齐多夫定代谢的计算模型。
Biochem J. 2005 Dec 1;392(Pt 2):363-73. doi: 10.1042/BJ20050749.
9
Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.人脱氧核糖核苷激酶和核糖核苷激酶对抗病毒和抗癌核苷类似物的底物特异性及磷酸化作用
Pharmacol Ther. 2003 Nov;100(2):119-39. doi: 10.1016/j.pharmthera.2003.07.001.
10
Role of MRP4 and MRP5 in biology and chemotherapy.多药耐药相关蛋白4(MRP4)和多药耐药相关蛋白5(MRP5)在生物学及化疗中的作用
AAPS PharmSci. 2002;4(3):E14. doi: 10.1208/ps040314.